Survival difference between EGFR Del19 and L858R mutant advanced non-small cell lung cancer patients receiving gefitinib: a propensity score matching analysis

OBJECTIVE: Although superior clinical benefits of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in the treatment of advanced non-small-cell lung cancer (NSCLC) had been reported, the survival difference between exon 19 deletion (Del19) and exon 21 Leu858Arg substitution (...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Chin J Cancer Res
Main Authors: Zhuo, Minglei, Zheng, Qiwen, Zhao, Jun, Wu, Meina, An, Tongtong, Wang, Yuyan, Li, Jianjie, Wang, Shuhang, Zhong, Jia, Yang, Xue, Chen, Hanxiao, Jia, Bo, Dong, Zhi, Gao, Emei, Wang, Jingjing, Wang, Ziping
Formato: Artigo
Idioma:Inglês
Publicado em: AME Publishing Company 2017
Assuntos:
Original Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5775015/
https://ncbi.nlm.nih.gov/pubmed/29353978
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21147/j.issn.1000-9604.2017.06.10
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados